RESEARCH PAPER

Development of Sustained-Release Pastilles of a BCS Class III Antidiabetic Drug Using Melt Solidification Technique.

Mohit Kuamr[1], Neelam painuly[2], Akash Verma[3], Heena mittal[4]

[1]Assistant Professor, Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad-244001, U.P., India; mohitgoyal21111@gmail.com; 0009-0001-8236-7396.

[2]Associate Professor, School of Pharmacy & Research, Dev Bhoomi Uttarakhand University, Naugaon , Dehradun, India, neelu.painuly@gmail.com

[3]Assistant Professor, Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad-244001, U.P., India; aakashv.verma210@gmail.com; 0000-0003-0043-7854.

[4]Assistant Professor, Department of Pharmaceutics, Shri Guru Ram Rai University, Dehradun.

Corresponding Author: Mohit Kumar

Assistant Professor, Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad-244001, U.P., India; mohitgoyal21111@gmail.com; 0009-0001-8236-7396.

ABSTRACT

This study's overarching goal was to develop laboratory-scale manufactured melt solidification equipment in order to investigate the usage of solid lipid as an alternative to polymers and a solvent-free approach for formulation of sustained release dosage forms like pastilles. Pastilles with a slow release of metformin in hydrochloride were made using a melt solidification process. Box-Behnken designs were used as part of the response surface approach for optimization. We tested the device at 20G needle size and 4Â°C cooling plate temperature on a lab scale. The formed pastilles was examined for their size and shape, crushing strength, flow characteristics, contact angle,%friability,% drug content uniformity, and thermal properties by differential scanning calorimetry, assessment of pore formation done by scanning electron microscopic analysis. The lipid matrix showed sustained release during in vitro breakdown for up to 10 hours. More than 95% drug released was recorded at 10 h. The formed Pastilles were roughly spherical in shape and ranged in size from 2.5 mm to 3.5 mm, yet the pastilles' angle of contact was measured to be more than 115 degrees. The disintegration rate was increased, and the function played by pore former quantity was crucial. The past illation technique is an excellent method for creating pastilles that are the right size, shape, crushing strength, contact angle, and, most importantly, release their contents slowly over time.

Keywords: Meltsolidification Technique, Pastillation, Drug, Polymers, Calorimetry.

How to cite this article: Kuamr M, Painuly N, Verma A, Mittal H, Development of Sustained-Release Pastilles of a BCS Class III Antidiabetic Drug Using Melt Solidification Technique. Int J Drug Deliv Technol. 2026;16(4s): 303-315. DOI: 10.25258/ijddt.16.2s.37

Source of support: Nil

Conflict of interest: None

INTRODUCTION

The fact that diabetes is becoming more common in countries all over the globe draws attention to the urgent need for developing innovative means of administering medications. A particularly difficult component of diabetes treatment is the development of new delivery mechanisms for anti-diabetic drugs that are classified as belonging to the third class of the Biopharmaceutical Classification System (BCS) [1]. Because of their low permeability and solubility, these drugs often call for the development of novel methods of administration in order to achieve optimal therapeutic effects. It is possible that going beyond the realm of traditional dose forms will be required in order to achieve the desired effects of controlled and delayed pharmaceutical release [2].

Traditional delivery options for anti-diabetes medications include oral consumption (by pills, capsules, or needles) as well as intravenous injection. When dealing with BCS Class-3rd medications, however, these forms run into a number of restrictions

[3]. Many different drugs have poor solubility, which may lead to irregular absorption, which in turn can have a broad variety of effects on the therapeutic efficacy and safety of the medication. In addition, conventional techniques may not be able to control the rate of drug release adequately, which would mean that measures that deviate from accepted norms would be required to accomplish sustained release. [4]

In recent years, sustained-release pastilles have emerged as a promising new technique for the delivery of several types of drugs. The patient compliance rate, convenience of administration, and potential for controlled release kinetics are all improved with the use of these small, chewable dosage forms [5]. In addition to the more typical oral dosage forms, mastication, which is required for the absorption of medicine, may be accomplished with the use of pastilles. Sustained release pastilles for BCS Class-3rd anti-diabetic medications need to be developed in order to fully fulfill the potential that sustained release formulations have for enhancing the bioavailability of medications and the therapeutic efficacy of treatment [6].

The BCS Class-3rd anti-diabetic medications have a limited permeability and low water solubility, which are two of the most remarkable physicochemical properties of these medications. As a result of these challenges, the therapeutic pharmaceutical concentrations that are achieved at the site of action are often lower than expected. [7] The rapid elimination of these medications from the body is yet another aspect that may contribute to decreased patient compliance [8] The only way to get around these challenges is to go beyond the tried and true techniques of drug distribution and into innovative approaches that can be shaped to meet the particular characteristics of the treatments in question. This is the only way to ensure success. [9,10]

One of these cutting-edge methods that is drawing attention is known as melt solidification. A procedure that involves the solidification of a liquid mixture of the medicine and the excipient after it has been cooled. [11,12]This technique has a lot of potential for making long-lasting candies due to the fact that it may be used in a variety of situations. Modifying the temperature at which the medication melts, the rate at which it cools, and the amount of time it takes to solidify may be used to achieve the goal of controlling the rate at which the drug is released [13]. [13] Because it has the potential to solve the solubility and permeability problems that have hampered BCS Class-3rd medications up to this point, melt solidification has been the subject of a significant amount of study [14,15].`

Evidence from the existing body of literature demonstrates that there is a considerable dearth of research into the use of the melt solidification technique in the production of sustained release pastilles for BCS Class-3rd anti-diabetic medications. Because there hasn't been nearly enough comprehensive study done to fill this gap, our understanding of the technique's full potential for enhancing medicine delivery is limited [16]. Filling up this knowledge void is very necessary if we are going to improve the distribution of medications and fulfill the unmet treatment needs of diabetic patients.[17] The purpose of the current study is to investigate this hitherto uncharted territory by elucidating the complexities of melt solidification for the purpose of producing pastilles, which has the potential to alter the administration of BCS Class-3rd anti-diabetic medications [18,19]

Particularly BCS Class-3rd drugs have the potential to transform the environment around the distribution of anti-diabetic therapy. Innovative solutions are required to address the issues that are brought on by these treatments, and one such solution is the melt solidification method [20,21]. This study aims to provide new information that might potentially be utilized to enhance the formulation and use of sustained-release pastilles for the treatment of diabetes. In doing so, the researchers want to make a contribution to the evolving paradigm of medicine delivery [22–24].

REVIEW OF LITERATURE

Kim JW (2022) [22] these little pieces are called pastilles, and they are hardened lipid melt mass. Its advantages include the fact that it obviates the need for expensive machinery and power, and that it completely does away with the dust produced by cutting, grinding, crushing, and similar operations. Another perk is that no solvent is required for this method.Also, there is already advanced pastillaton technology in place in the chemical sector, which may be used for mass-scale manufacturing.

Thies C (2021) [23] Pastillation is another technique used in the chemical and agrochemical industries to solidify liquids and make them easier to handle than powdered chemicals. Pastilles are hemispherical solidified discrete units that have not yet been explored to their full potential in the pharmaceutical industry, specifically for dmg delivery systems..

OBJECTIVES

- To study the Equipment for making solid lipid-based pastilles by melting and then solidifying the mixture.
- To study the device processing optimization for certain parameters.
- TO study the influence of the pore former on MET HCl sustained release product release

rate.

STATEMENT OF THE PROBLEM

Due to its features, BCS Class-3rd anti-diabetic medication sustained release pastilles are difficult to design. These medicines' limited solubility and permeability hinders therapeutic effects. Innovative methods may be needed to regulate and extend medication release from conventional drug delivery devices. The literature shows a void in research on melt solidification for prolonged release medication pastilles. Drug bioavailability, therapeutic results, and diabetes control must be improved by closing this gap. A concentrated study of melt solidification is needed to overcome the present constraints in BCS Class-3rd anti-diabetic medication delivery systems.

RESEARCH METHODOLOGY

Lucknow, India graciously gave MET HCl. Glyceryl monostearate and potassium chloride came from Nashik, India. Analytical grade hydrochloric acid, disodium hydrogen phosphate, and sodium hydroxide were procured. Gelatin capsule shell from Nashik, India.

Melt solidification equipment fabrication

Using a glass syringe with a plunger, a hypodermic metal needle (20 G), a heating jacket, an automated temperature controller, a stand with a holder, and an ice plate, a laboratory-scale, in-house assembly device was created.

Procedures in Action

The wax/lipid, medication, and excipients were all melted together and put into the glass syringe. An automated timeproof auto cut regulator type transformer was used to provide power to a heating coil housed in a jacket assembly enclosed in a glass syringe. For compounds with low melting points, a water jacket heating assembly may be used instead. For high melting points compounds, liquid paraffin is utilized in the jacket instead of water. The homogeneous distribution of heat provided by a liquid jacket makes it feasible to maintain a solid lipid substance in a molten state for an extended period of time. Just below the tip of syringe assembly, there is cooling plate on to that drops of molten substance falls and that drops quickly become harden owing to cooling temperau1re of plate regulated by resting the plate on ice cube. By manually pushing the molten mass with a plunger, the size of the pastilles may be adjusted.Important variables were considered in the screening study's placebo pastille formulation, including needle size, drop height, and cooling plate surface temperature.

Pastille making using solid lipid (glyceryl monostearate)

StepI

At 65 degrees Celsius, solid lipid glyceryl monostearate was melted in a paraffin oil bath.

StepII

Separate batches of MET HCl medication were melted at 210°C to 220°C in an oil bath assembly.

StepIll

A melted mass of fat was mixed with a suspension of finely powdered potassium chloride (KCl) pore former and dmg, which was then agitated frequently to achieve homogeneity.

StepVI

This uniform mixture was then transferred to a glass syringe assembly heated in a constant-temperature water heater jacket; once the syringe was heated, a hypodermic needle was used to release the molten mass onto a cooling base plate, where it quickly solidified into hemispherical pastilles. Pastilles of this asymmetrical form were carefully scraped off the cooling plate using a sharp knife. The resulting pastilles formulation was then transferred to a size "0" capsule shell.

Box-Behnken design for experiments

The Design of Expert program (version 13.0.5.0, Stat Ease) in Minneapolis, USA was used to compute formulation batches using a Box-Behnken design with three elements and three levels. “Using the three midpoints, we get 15 minutes. Pastille formulation was studied to find the optimal combination of ingredients using RSM.

Table 1: Batches of formulation based on a 3-factor, 3-level system: Constants and their reactions

Batchcode	Factors			Y%CCRresponse
	X1	X2	X3	
F1	0	-1	**-1**	96.68
F2	1	0	1	85.14
F3	0	0	0	97.44
F4	-1	-1	**O**	96.35

F5	0	1	1	95.78
F6	0	0	0	97.41
F7	0	-1	1	90.25
F8		1	0	88.16
F9	1	0	-1	89.58
F1O	-1	1	O	96.93
F11	-1	O	-1	98.89
F12	-1	O		95.45
F13	1	-1	O	84.54
F14	0	1	-1	96.95
F15	0	0	0	97.38

The following operational factors were taken into account,

(Xl):Solid lipid glycerol monostearate (GMS)

(X2):Pore-forming KCl

(X3):Descending from the height of the cooling plate,

Above three components was an in-dependable variable which are examined at three levels. In contrast to the % cdr (Y*), which was a stable factor,

Table 2: Box-Behnken design's factors and levels.

Factors		X1=Solid- lipid GMS (mg)	X2=Pore former KCI (mg)	X3=Dropping Height (cm)
Levels used	**-1 (low)**	1000	50	0.5
	0 **(mid)**	1500	100	1
	1 (high)	2000	150	1.5

Definition of Pastilles

The color, diameter, sphericity, and smoothness of the surfaces of Fl-Fl5 pastilles were measured and analyzed.

Table 3: Results of a Physical Examining

Formulation batches	Color	Shape	Size (diameter)	Texture
F1 to F15	White	Hemispherical	2.5± 0.2 to 3.5 ±0.3mm	Smooth surface

Identifying contact angles
Pastille's flow attribute is measured by contact ru1gle. The contact angle of the formed pastilles against the metallic plate was measured using a photographic technique. This shot of a pastille was taken from above, and the image was enlarged proportionally in Photoshop. The formula below was used to manually determine the contact angle of the formulated pastilles.

$$\theta = 2\,tan^{-1}\frac{2h}{d}$$

Coded terms,

h:Form foundation for solidified drop height.

d: For solidified drop diameter

Dimensions from pastilles photos and contact angle were determined.

Consistency in drug composition
The drug's concentration was calculated by dissolving 500 milligrams of MET HCl in 20 milliliters of distilled water in a 100 milliliter volumetric flask. After then sonicated for 10 min and then maintain it to cool at normal condition at 25°C room temperature, with distilled water the remainder volume was created up to the mark. 10 ml of the aforesaid solution were then filtered using 0.45 um filter then it was dilute precisely with distilled water then evaluated at 233.5 nm on UV spectrophotometrically and drug concentration was estimated using equation.

The % drug content was determined by preparing a standard drug solution in the same way as stated above.

$$X = Y \pm \frac{C}{M}$$

In addition, the percentage of drug content was calculated from the concentration, as shown in the eq..:

$$\%\,\text{drug content} = \frac{\begin{matrix}\text{concentration of drug}\\ \text{in sample solution}\end{matrix}}{\begin{matrix}\text{Equivalent concentration}\\ \text{of standard drug}\end{matrix}} \times 100$$

Fluid dynamics
Several tests, including bulk density and tapped density, were conducted on the formed pastilles to ensure their flow qualities.

Evaluation of percent friability
A sample of 2000 mg pastilles was weighed and recorded to determine its friability. A friability test was performed by inserting the material into a clear, revolving cylinder. After 4 minutes of processing at 25 revolutions per minute, the test pastilles were withdrawn and reweighed. Losses in weight due to friability were computed by plugging weights into the following formula.

$$\%F = \frac{Wo - Wf}{Wo} \times 100$$

Where,

Wo: Pre-test sample mass

Wf: Analysis of sample mass

Friability weight losses of less than 0.1% are considered pass requirements per IP.

Testing the ability to crush or shatter
The capacity to crush and break was measured so that the fracture pattern produced by the punch could be compared to the force applied to the pastille. Crushing strength was evaluated using a texture analyzer. Mechanical texture analysis model CT3, developed in Brookfield, Germany, was used to analyze data on the crushing strength of optimized batch F5 pastilles before and after being subjected to a dissolving test.

Scanningelectronmicroscopicstudy(SEM)
High and low resolution scanning electron microscopy instruments were used to examine the surface texture of the pastilles made from the optimized batch F5.

Fouriertransformsinfrared spectroscopy(FTIR) Spectroscopy
FTIR may be used to find out things like the quantity of components in a combination, the quality of a sample being tested, and the identification and confirmation of unknown items or known materials using reference data. The ATR technique was used to prepare the samples, making it feasible to directly analyze the FTIR spectra of the samples. By placing the sample on a high refractive index prism and pressing down on the knob, an IR beam of light is sent through the prism, entirely reflected, and then scanned between 400 and 4000 cm-1 to obtain an infrared spectrum of the sample. The FTIR spectrophotometer (FT/IR 4600 Jasco) was utilized for the analysis. Functional group peaks were identified in the FTIR spectra and compared to standard references.

DSE
Instrument star system differential scanning calorimetrty (DSC 1), mettlertoledo, Switzerland, linked to sub-ambient assembly of liquid nitrogen, was used for optimum batch F5. The instrument is operated at a flow rate of 100 ml/min while purged with nitrogen gas. A 2-10 mg sample was weighed in an open aluminum pan,

and the temperature was increased by 10 °C/min between 30 and 300 °C.

Research on Drug Absorption and Distribution

The drug release profile of each batch of produced pastilles was analyzed using the USP II dissolving test instrument (make Electrolab TDT 8 L). For the first 2 hours, a 900-ml acidic buffer was used as the dissolution medium, and the internal temperature of the a11d basket was kept at 37.5 0.5°C while the machine ran. After 2 hours, the buffer solution was changed to a phosphate buffer with a pH of 6.8, and the machine ran for another 10 hours. Pipette aliquots of 10 ml were collected at regular intervals during the dissolving, and the sink condition was kept at the same temperature and pressure throughout. After that, UV spectrophotometric measurement was performed at 233.5 nm to record the absorbance of the sample.

Establishing the release mechanism and kinetics

Model fitting data was obtained after dissolution calculations were performed in order to investigate the release kinetics and mechanism.

Test of Stability

According to worldwide conference on harmonization recommendations, the F5-batch pastilles were maintained in 25 ml of high density polyethylene packing container, correctly sealed, and kept at roughly 40°C retained at 75% relative humidity in the stability chamber for a defined length of 3 months. One-month, two-month, and three-month samples were evaluated for % dmg release.

RESULTS AND DISCUSSION

We used a melt solidification device we built in the lab to make hemispherical pastilles containing MET HCl. Several operational factors affecting the melt solidification equipment were analyzed. Next batches of placebo pastilles were created using the assessed restrictions. Increasing the needle orifice from 14G to 20G resulted in a corresponding increase in the pastilles' size, from 2.5 ±0.1 mm to 3.5 ±0.1 mm, and the contact angle of the pastilles was found to be directly connected to the kind of cooling plate and its temperature. Study demonstrated quick solidification takes occur on metallic surface at 4°C regulated cooling temperature, whereas the conversion from molten lipid to solidified state takes the most time on glass and plastic surfaces due to their poor conductor of heat. Research also showed that the release of ondmg from pastilles might be influenced by a change in falling height.As such; it was treated as such in a factorial design research. The results of the experiments and statistical analysis showed that the best solidification occurred at a cooling temperature of 4 °C± 0.1 °C, with a needle size of 20 G, on a cooling plate made of metal.

Formulated pastille testing

Contact-angle determination

The contact angle of molten drop aBer fall on the cooled surface was used to analyze solidification spreading. The research on pastilles found that contact angles over 90° are more accurate for hemispherical pastilles and important for excellent flow in large-scale manufacturing. Pastilles of formulation batch Fl-Fl5 had 105°-115° contact angles [Table 4]. This suggests that molten lipid viscosity creates hard pastilles on cooling plate to improve contact angle.

Table 4:Flow characteristics

Flow Chrematistics	Poor	Fair	Good
Angle of contact	60-85^0	85-105^0	105-125^0

Evaluation of transportability, friability, and active ingredient concentration

Pastilles' fluidity was analyzed using a bulk and tapped density test, the results of which were derived using a formula.

$$Bulk\ density\left(\frac{gm}{ml}\right)=\frac{weight\ of\ pastilles}{initial\ bulk\ volume}$$

$$Tapped\ dinsity\left(\frac{gm}{ml}\right)=\frac{weight\ of\ pastilles}{tapped\ volume}$$

The percentage of weight loss due to friability was calculated using the following formula: % friability = (average of starting weight in grams) minus (average of final weight in grams) / (average of initial weight in

grams) x (average of initial weight in grams) x 100. The data was carefully documented.

Table 5: Density, tap density, drug content, and friability results

Test	Bulk density	Tapped density	Drug content	Friability
Batches F1 tot F15	0.562-0.813 g/ml	06769-0.876 g/ml	95.6-99.8 %	0.10%
Remark	Good flow	Excellent flow	Uniform Drug content	Passed

We see the DSC curves of MET HCl, glyce1yl monosterate, and the optimized formulation batch FS, as well as their energy states at the phase transition temperature. The melting of MET HCl verified by endothermic peak at 221-222°C, and at 59-60°C for glyceryl monosterate.

Studies using scanning electron microscopy

For this reason, SEM examination of the formed pastilles of the optimized batch FS is crucial in understanding the drug release behavior of pastilles without inducing erosion. Optimized batch pastilles seemed spherical in shape, and their surface texnire was consistent, as shown in Figure, which was taken at a reduced magnification.

Image of pastilles taken at a greater magnification showing the improved batch's surface, where more c1ystalline structural flakes may be observed.

SEM picture of pastilles after being exposed to dissolving media reveals the presence of pores on the surface. Therefore, the distribution of solid- lipid detected at greater magnification entering the aqueous medium inside the pastilles' interior. This suggests that the pastilles' pore formation is responsible for the release of the trapped medication.



Figure1:Images of the improved formulation f5 as seen by scanning electron microscopy Images (a) before putting into the dissolution media at the standard magnification (b) before placing into the dissolution medium at a higher magnification (c) and (d) after placing into the dissolution medium at the standard magnification.

Study of Dissolution in a Petri Dish

To determine the influence of glyceryl monostearate, a solid lipid matrix forming agent, on the release of dmg from the pastilles for sustained release in dissolution mediums, an in vitro dissolution study was conducted using batches F1 to F15 of the formulated pastilles.

Partially releasing 80% of dmg after 10 hours in the batch F0 (no pore former) [Figure 6b].Because the lipid membrane prevents the dissolving medium from penetrating to the entrapped drug inside the pastilles, only the drug that has been adsorbed to the surface of the pastilles is released. The pore former method, which included the inclusion of KCL, was used to obtain full release of the whole dosage of medication from the pastilles. The rate of dissolution was shown to increase in proportion to the number of pores present.

Drug release percentage affected by pore former

The amount of lipid and the height from the needle tip to the cooling plate were held constant (F7 and FS, F4 and Fl0) to isolate the effect of the pore generating agent on drug release.

Table 6: Batches F7, F5, F4, and F10 of a Compared Formulation

Batch code		F7	F5	F4	F10
Factor	**X1 (solid lipid)**	0	0	-1	-1
	X2 (Pore Former)	-1	1	-1	1

	X3 (height)	1	1	0	0

It was found during the dissolution research that the adsorbed dmg, that is, the dmg existing on the surface of the pastilles, was first released, creating pinholes within the pastilles and allowing the dissolution medium to penetrate inside the pastilles to reach the dmg contained in the matrix. It was established that greater the quantity of pore former incase of (FS), maximal the number of pinholes formed into pastilles. So, stuff as much of the dissolving media as possible into the pastilles' centers. Smdy demonstrated that the release mechanism by which medication was released from pastilles was diffusion, it was viewed as the rate determining element in the dissolution. The link between lipid content and candy size is therefore better understood.

Drug absorption and the role of lipid content

It was determined that dmg entrapment in lipid matrices is at its least when lipid concentrations are at their lowest. However, this may lead to insufficient drug release if the increase in lipid content has other consequences. As may be seen from (F2 and F12; F9 and Fll), solid-lipid concentration significantly affects drug release.

Table 7:Formulation lots F2 and F12, F9 and F10 compared

Batch code		**F2**	**F12**	**F9**	**F10**
Factor	**X1 (solid lipid)**	1	-1	1	-1
	X2 (Pore Former)	0	0	0	0
	X3 (height)	1	1	-1	-1

Height change and medication release

It was found that the size of the pastilles created was directly related to the height at which they were dropped. If the distance between the needle and the cooling base plate is large, the drop of melted mass that falls from the needle becomes flatter, resulting in a lower contact angle and release, and if the distance is small, hemispherical-shaped pastilles are produced, resulting in a higher contact angle and release and better flow properties. These parameters have a noticeable impact on (F7 and Fl; F14 and FS; F12 and Fll). Response surface plots were also used to determine how much of an effect these operational conditions had on drug release.

Table 8: Batches F7, F1, F14, and F5 were used to establish a comparison.

Batch code		**F7**	**F1**	**F9**	**F14**	**F5**	**F12**	**F11**
Factor	**X1 (solid lipid)**	0	0	0	0	0	-1	-1
	X2 (Pore Former)	-1	-1	1	1	1	0	0
	X3 (height)	1	-1	-1	1	1	1	-1

How and why a substance is released

Based on the numerical value of Korsmeyer-Peppas (n), which was determined to be 0.6304, and the 0.978 con-

elation coefficient, it was inferred that the system followed a non-Fickian first order drug release model with an optimized batch F5 distribution. This might have occurred because of how glyceryl monostearate diffuses and relaxes in the dissolving media.

Box-Behnken design for analyzing response surfaces

The statistical correlation between components as well as variables was described byRSM. Response surface plots helped comprehend the overall effect of several variables (such as X1) in the experiment. The data fits using quadratic model and significant with F value 408.69. And the program even did the analysis of variance for you.

Table 9: Analyses of variance results for a set of response variables Analysis of Variance Quadratic Model

Source	Sum ofSquares	MeanSquare	df	P-value	F-value	
Model	328.68	36.52	9	<0.0001	408.69	(S)
C-Height	29.95	29.95	1	<0.0001	335.20	
B-KCI	12.50	12.50	1	<0.0001	139.88	
A-GMS	202.01	202.01	1	<0.0001	2260.58	
AB	2.31	2.31	1	0.0038	25.85	
A2	67.72	67.72	1	<0.0001	757.79	
BC	6.92	6.92	1	0.0003	77.40	
AC	0.2500	0.2500	1	0.1553	2.80	
B2	9.84	9.84	1	0.0001	110.12	
LackofFit	0.4450	0.1483	3	0.0060	164.81	(S)
Residual	0.4468	0.0894	5			
c2	2.75	2.75	1	0.0026	30.74	
PureError	0.0018	0.0009	2			
Cor Total	329.13		14			

Equation (8) displays the relationship between the factors and the reaction of the cumulative release of drug expressed as a percentage.

$$\%CDR=+97.41-5.03A+1.25B-1.94C+0.7600AB-0.2500AC+1.32BC-4.28A^2-1.63B^2-0.8625C^2$$

Coded values, A for glyceryl monostearate quantity, B for KC! amount, and C for height of needle from cooling plate.

The optimal amounts of glycerol monostearate (1351.185 mg), potassium chloride (146.750 mg), and height (0.807 cm) were determined using experimental design.

GMS's Impact

We have a 3D response surface graph depicting the link between these three independent variables. The research showed that less glyceryl monostearate and a higher quantity of the pore-forming ingredient resulted in more medication release. Drug trapping in the lipid matrix decreased with decreasing GMS concentration. According to [Figure 7], the optimum range of GMS for prolonged medication release is between 1000 and 1500 mg. It was shown that the rate at which pastilles released drug was positively correlated with both height and KCl.



Figure2:Height and the drug-release-inhibiting effects of glyceryl monostearate.

The KCl Effect

By holding the lipid concentration and needle height constant, we were able to evaluate the impact of the pore former on the drug release percentage. The pastilles were absorbing the dissolving medium. Increased access to the pastille's interior core from dissolving medium is achieved by increasing the pore former concentration." By increasing the surface area of pastilles with pore formers, we may increase their rate of breakdown.

Height's Impact

Droplet height as it falls from the needle to the cooling plate was found to be associated with the size and shape of the formed pastilles. The hemispherical design of the pastilles provides higher contact angle allowing optimal drug release. In addition, when the amounts of solid-lipid and pore former are maintained constant, there is an inverse relationship between the contact angle of pastilles and the rate at which drug is released.

Stabilitystudies

The formulation's long-term stability was studied in a stability study. At accelerated circumstances of temperature and humidity, it was found that the formulation-optimized batch FS consistently lasted for 3 months. The physical characteristics, % drug content, and in l'itro dissolution of pastilles were all shown to be stable over time.

Table 10: Comparison of the initial (0-day) and final (3-month) drug release patterns from an improved batch of f5 (n = 3).

Time (Hrs.)		0	2	4	6	8	10
Cumulative % drug release	**Initial sample**	11	20	60	78	92	100
	Stability sample	11	20	60	90	93	100

The purpose of this work was to develop a novel melt-solidification technique for formulating sustained-release pastilles of MET HCl, a type-II anti-diabetic drug in BCS Class III. These pastilles have a hemispherical shape and release the drug slowly over time. The laboratory created and successfully employed the melt solidification equipment, which was then optimized for the manufacturing of pastilles [25]. Physical properties, spectrophotometric examination, and Fourier transform infrared spectra, as well as thermal behavior by differential scanning calorimetry (DSC), all corroborated the substance's identify as MET HC! It was also via a literature search that lipid-based excipients such glyce1yl monostearate and stearic acid

were chosen. An FTIR analysis was performed to look for any potential interactions between drug and lipid excipients, and the results were negative. [26,27] After melting a mixture of drug and lipid at a predetermined temperature, a drop of the molten mass was poured into a preheated syringe of a droplet solidification apparatus and then dropped onto a cooling plate, where it solidified into the pastilles (a hemispherical shape units). The medication content, contact angle, and SEM/DSC analysis of these pastilles were all considered. Separate formulation batches was generated by employing glyceryl monosterate and stearic acid with various pore forms such as KCl ,Polaxomer 407 and polyethylene glycol (PEG) 4000, PEG 6000. [28,29] Drug release from pastilles is affected by the total quantity of lipids and pore formers. Up to l O hours of drug release was seen in the FS batch of drug when glyceryl monostearate was used. Optimized formulation achieved from by Box-Behnken design of respective lipid excipients for the sustained release drug delive1y was developed and assessed then compared with FS batch. No statistically significant differences were found. [30]

CONCLUSION

Melt solidification equipment was easy to build and also cost efficient for small-scale development of formulation batches. Dmg release from a lipid matrix was tested using a pore forming to modify the release rate.

7.1 Findings of the study

In house lab scale designed pastillation equipment was successfully created and was employed to make pastilles. This is the straightforward approach to construct continuous release Metformin HCl Lipid-based multi-particle candies It was found that glyceryl monostearate and glyceryl monostearate were the best solid lipid materials for creating sustained released pastilles with water-soluble medication.

7.2 Scope for further research

The characteristics of the melt solidification process, such as melting temperature, cooling rate, and solidification duration, will be the focus of future investigation. In order to find the best formulation for sustained release pastilles, it is also important to investigate the effect of different excipients on the solidification process. To ensure the solidified pastilles are an effective delivery mechanism for BCS Class-3rd anti-diabetic medicines, characterization experiments will be performed to evaluate their physical and chemical characteristics.

REFERENCES

1. Fralick M, Jenkins AJ, Khunti K, Mbanya JC, Mohan V, Schmidt MI. Global accessibility of therapeutics for diabetes mellitus. Nat Rev Endocrinol 2022;18:199. https://doi.org/10.1038/S41574-021-00621-Y.
2. Xu X;, Wang X;, Jiang H, Xu X, Wang X, Jiang H. Current Status and Prospect of Diabetes Diagnosis and Treatment Based on Biosensing Technology. Chemosensors 2023, Vol 11, Page 391 2023;11:391. https://doi.org/10.3390/CHEMOSENSORS11070391.
3. Mastropietro D, Park K, Omidian H. Polymers in oral drug delivery. Comprehensive Biomaterials II 2017:430–44. https://doi.org/10.1016/B978-0-12-803581-8.09291-2.
4. Nyamba I, Sombié CB, Yabré M, Zimé-Diawara H, Yaméogo J, Ouédraogo S, et al. Pharmaceutical approaches for enhancing solubility and oral bioavailability of poorly soluble drugs. European Journal of Pharmaceutics and Biopharmaceutics 2024;204:114513. https://doi.org/10.1016/J.EJPB.2024.114513.
5. Hans Raj JGD. Emerging Frontiers In Sustained Release Drug Delivery Systems: Unveiling The Latest Innovations And Future Perspectives. International Journal of Pharmaceutical Sciences 2023;01:186. https://doi.org/10.5281/ZENODO.8267084.
6. Martínez E, Gamboa J, Finkielstein C V., Cañas AI, Osorio MA, Vélez Y, et al. Oral dosage forms for drug delivery to the colon: an existing gap between research and commercial applications. Journal of Materials Science: Materials in Medicine 2025 36:1 2025;36:24-. https://doi.org/10.1007/S10856-025-06868-5.
7. Wang S, Liu D, Ouyang D. Quantitative analysis of excipients to the permeability of BCS class III drugs. Int J Pharm 2025;668:124958. https://doi.org/10.1016/J.IJPHARM.2024.124958.
8. Chillistone S, Hardman JG. Modes of drug elimination and bioactive metabolites. Anaesthesia & Intensive Care Medicine 2023;24:482–5. https://doi.org/10.1016/J.MPAIC.2023.05.011.
9. Tambe V, Sirsat B, Rajpoot K, Gadeval A, Tekade RK. Pharmacogenomics and drug metabolism. Biopharmaceutics and Pharmacokinetics Considerations: Volume 1 in Advances in Pharmaceutical Product Development and Research 2021:355–85. https://doi.org/10.1016/B978-0-12-814425-1.00021-8.
10. Barreto EF, Larson TR, Koubek EJ. Drug Excretion. Reference Module in Biomedical Sciences 2021. https://doi.org/10.1016/B978-0-12-820472-6.99999-7.

11. Tiwari A, Samanta R, Chattopadhyay H. Droplet solidification: Physics and modelling. Appl Therm Eng 2023;228. https://doi.org/10.1016/j.applthermaleng.2023.120515.
12. Lee YP, Ro ST. Two Dimensional Analysis of the Solidification Process including Effect of the Mushy Zone. Transport Phenomena in Heat and Mass Transfer 1992:651–62. https://doi.org/10.1016/B978-0-444-89851-7.50061-3.
13. Pereira GG, Figueiredo S, Fernandes AI, Pinto JF. Polymer Selection for Hot-Melt Extrusion Coupled to Fused Deposition Modelling in Pharmaceutics. Pharmaceutics 2020, Vol 12, Page 795 2020;12:795. https://doi.org/10.3390/PHARMACEUTICS12090795.
14. Zhang J, Feng X, Patil H, Tiwari R V., Repka MA. Coupling 3D printing with hot-melt extrusion to produce controlled-release tablets. Int J Pharm 2017;519:186–97. https://doi.org/10.1016/J.IJPHARM.2016.12.049.
15. Alomari M, Mohamed FH, Basit AW, Gaisford S. Personalised dosing: Printing a dose of one's own medicine. Int J Pharm 2015;494:568–77. https://doi.org/10.1016/J.IJPHARM.2014.12.006.
16. (PDF) A review on solubility enhancement of Biopharmaceutical Classification System Class II drugs using bilayer tablet technology n.d. https://www.researchgate.net/publication/353934503_A_review_on_solubility_enhancement_of_Biopharmaceutical_Classification_System_Class_II_drugs_using_bilayer_tablet_technology (accessed January 21, 2026).
17. Bost JP, Barriga H, Holme MN, Gallud A, Maugeri M, Gupta D, et al. Delivery of Oligonucleotide Therapeutics: Chemical Modifications, Lipid Nanoparticles, and Extracellular Vesicles. ACS Nano 2021;15:13993–4021. https://doi.org/10.1021/ACSNANO.1C05099.
18. Khvorova A, Watts JK. The chemical evolution of oligonucleotide therapies of clinical utility. Nat Biotechnol 2017;35:238–48. https://doi.org/10.1038/NBT.3765.
19. Bost JP, Barriga H, Holme MN, Gallud A, Maugeri M, Gupta D, et al. Erratum: Delivery of Oligonucleotide Therapeutics: Chemical Modifications, Lipid Nanoparticles, and Extracellular Vesicles (ACS Nano (2021) 15:9 (13993-14021) DOI: 10.1021/acsnano.1c05099). ACS Nano 2021;15:18590–1. https://doi.org/10.1021/ACSNANO.1C09275.
20. Cheng CL, Yu LX, Lee HL, Yang CY, Lue CS, Chou CH. Biowaiver extension potential to BCS Class III high solubility-low permeability drugs: Bridging evidence for metformin immediate-release tablet. European Journal of Pharmaceutical Sciences 2004;22:297–304. https://doi.org/10.1016/j.ejps.2004.03.016.
21. Cho HY, Yoon H, Lim YC, Lee YB. Pharmacokinetics and bioequivalence evaluation of gliclazide/metformin combination tablet and equivalent doses of gliclazide and metformin in healthy Korean subjects. Int J Clin Pharmacol Ther 2009;47:770–9. https://doi.org/10.5414/CPP47770.
22. Garza-Ocañas L, González-Canudas J, Tamez-de la O E, Badillo-Castañeda C, Gómez-Meza MV, Romero-Antonio Y, et al. Comparative Bioavailability of Metformin Hydrochloride Oral Solution Versus Metformin Hydrochloride Tablets in Fasting Mexican Healthy Volunteers. Adv Ther 2019;36:407–15. https://doi.org/10.1007/s12325-018-0853-3.
23. Crison JR, Timmins P, Keung A, Upreti V V., Boulton DW, Scheer BJ. Biowaiver approach for biopharmaceutics classification system class 3 compound metformin hydrochloride using In Silico modeling. J Pharm Sci 2012;101:1773–82. https://doi.org/10.1002/jps.23063.
24. Petruševska M, Berglez S, Krisch I, Legen I, Megušar K, Peternel L, et al. Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Levetiracetam. J Pharm Sci 2015;104:2676–87. https://doi.org/10.1002/jps.24350.
25. Wadher K, Kakde R, Umekar M. Formulation and Evaluation of a Sustained-Release Tablets of Metformin Hydrochloride Using Hydrophilic Synthetic and Hydrophobic Natural Polymers. Indian J Pharm Sci 2011;73:208. https://doi.org/10.4103/0250-474X.91579.
26. Chen HC, Mendelsohn R, Rerek ME, Moore DJ. Fourier transform infrared spectroscopy and differential scanning calorimetry studies of fatty acid homogeneous ceramide 2. Biochim Biophys Acta Biomembr 2000;1468:293–303. https://doi.org/10.1016/S0005-2736(00)00271-6.
27. Fourier transform infrared spectroscopy and differential scanning calorimetry studies of fatty acid homogeneous ceramide 2. | Semantic Scholar n.d. https://www.semanticscholar.org/paper/Fourier-transform-infrared-spectroscopy-and-studies-Chen-Mendelsohn/fb3b032f2d50fef8593b7134e3c94ae3295fc981 (accessed January 21, 2026).
28. Newa M, Bhandari KH, Li DX, Kim JO, Yoo DS, Kim JA, et al. Preparation and evaluation of immediate release ibuprofen solid dispersions

using polyethylene glycol 4000. Biol Pharm Bull 2008;31:939–45. https://doi.org/10.1248/BPB.31.939.

29. Preparation and Evaluation of Immediate Release Ibuprofen Solid Dispersions Using Polyethylene Glycol 4000 | Request PDF n.d. https://www.researchgate.net/publication/5400300_Preparation_and_Evaluation_of_Immediate_Release_Ibuprofen_Solid_Dispersions_Using_Polyethylene_Glycol_4000 (accessed January 21, 2026).
30. Yang YT, Di Pasqua AJ, Zhang Y, Sueda K, Jay M. Solid dispersions of the penta-ethyl ester prodrug of diethylenetriaminepentaacetic acid (DTPA): Formulation design and optimization studies. Pharm Dev Technol 2014;19:806–12. https://doi.org/10.3109/10837450.2013.836216.